- An Indian company, Panacea Biotec, is nearing a breakthrough with what could be the country's first indigenous, single-shot dengue vaccine, DengiAll, after two decades of development.
- The vaccine, which uses a weakened dengue strain developed by the US National Institutes of Health, is designed to be effective against all four dengue serotypes and can be administered to individuals who have not previously been infected.
- The vaccine’s formulation is also stable for three years at standard refrigeration temperatures.
- Phase three human trials for DengiAll commenced in August 2024, enrolling over 10,000 volunteers across India, with regulatory approval anticipated around 2027.
- Currently, only two dengue vaccines, Qdenga and Dengvaxia, are available, both with limitations regarding dosage, prior infection status, or efficacy against certain serotypes.
IN FULL
